{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Luan T"],"funding":["Key Research and Development Program of Shaoyang Science and Technology Bureau","Study of the Carcinogenic Mechanisms and Molecular Characteristics in Primary Pulmonary Lymphoepithelioma-like Carcinom","Development and Industrialization of a Robotic Bronchoscopy Platform","Major Project of Guangzhou National Laboratory","National Natural Science Foundation of China","Plan on enhancing scientific research in GMU"],"pagination":["2629081"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12915762"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["22(1)"],"pubmed_abstract":["Human Epidermal Growth Factor Receptor 2 (HER2) mutations account for approximately 3% of non-small cell lung cancer (NSCLC) patients. Currently, targeted therapies for HER2-mutant NSCLC include HER2 tyrosine kinase inhibitors (TKIs) and HER2 Antibody-drug conjugates (ADC). However, resistance often develops, and effective treatments for HER2 mutations remain lacking. We report a case of HER2-mutant lung adenocarcinoma where the patient developed resistance and severe interstitial lung disease following antibody-drug conjugate therapy. A highly biomimetic Human Organoid (HO) platform was employed to screen potential therapeutic options for the patient. The HO results indicated efficacy of Sunvozertinib and ineffectiveness of ADC, with maximum half-maximal inhibitory concentration (IC<sub>5"],"journal":["Human vaccines & immunotherapeutics"],"pubmed_title":["Personalized treatment of HER2-positive lung adenocarcinoma using Human Organoid Drug Sensitivity Test."],"pmcid":["PMC12915762"],"funding_grant_id":["2024B03J0862","GMUCR2024-01011","82570007","GZNL2023A02011","2025B1111010001","2024GZ2023"],"pubmed_authors":["Yao L","Luan Y","Chen Q","Fu S","Luan T","Xie X","Mo J","Lin X","Liu W","Wang L","Zhong N","Jin H","Chenli Z","Yu B","Wang S","Zhang Y","Zhou C","Ma H","Ma K","Yang Q","Xu Y","Lv Q"],"additional_accession":[]},"is_claimable":false,"name":"Personalized treatment of HER2-positive lung adenocarcinoma using Human Organoid Drug Sensitivity Test.","description":"Human Epidermal Growth Factor Receptor 2 (HER2) mutations account for approximately 3% of non-small cell lung cancer (NSCLC) patients. Currently, targeted therapies for HER2-mutant NSCLC include HER2 tyrosine kinase inhibitors (TKIs) and HER2 Antibody-drug conjugates (ADC). However, resistance often develops, and effective treatments for HER2 mutations remain lacking. We report a case of HER2-mutant lung adenocarcinoma where the patient developed resistance and severe interstitial lung disease following antibody-drug conjugate therapy. A highly biomimetic Human Organoid (HO) platform was employed to screen potential therapeutic options for the patient. The HO results indicated efficacy of Sunvozertinib and ineffectiveness of ADC, with maximum half-maximal inhibitory concentration (IC<sub>5","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Dec","modification":"2026-07-09T11:05:17.966Z","creation":"2026-07-09T10:39:20.401Z"},"accession":"S-EPMC12915762","cross_references":{"pubmed":["41700896"],"doi":["10.1080/21645515.2026.2629081"]}}